<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00329238</url>
  </required_header>
  <id_info>
    <org_study_id>1160.47</org_study_id>
    <secondary_id>2005-002536-94</secondary_id>
    <nct_id>NCT00329238</nct_id>
  </id_info>
  <brief_title>Secondary Prevention of Venous Thrombo Embolism (VTE).</brief_title>
  <acronym>RE-MEDY</acronym>
  <official_title>A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The general aim of this study is to determine the comparative safety and efficacy of
      dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR)
      of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous
      thromboembolism in patients who have been successfully treated with standard doses of an
      approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous
      Thrombo-embolism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Recurrent VTE or VTE Death at 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Recurrent VTE or VTE Death at 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Recurrent VTE or All Cause Death at 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Recurrent VTE or All Cause Death at 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep Vein Thrombosis (DVT) at 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DVT at 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Pulmonary Embolism (PE) at 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>Symptomatic pulmonary embolism (PE) at 36 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Pulmonary Embolism (PE) at 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>Symptomatic pulmonary embolism (PE) at 18 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deaths Related to VTE at 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>Deaths related to VTE (i.e. fatal PE) at 36 Months. Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deaths Related to VTE at 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deaths of All Causes at 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>Deaths of all causes at 36 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deaths of All Causes at 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>Deaths of all causes at 18 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Events</measure>
    <time_frame>first intake of study drug until 6 days following last intake of study drug</time_frame>
    <description>MBE (major bleeding event) if it fulfilled at least one of the following criteria
Fatal bleeding
Symptomatic bleeding in a critical area or organ.
Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.
Minor bleeding event was any bleeding that did not fulfil any of the criteria for MBEs
CRBE (clinically relevant bleeding event) if it is a minor bleeding events which fulfilled at least one of the following criteria
Spontaneous skin haematoma ≥25 cm2
Spontaneous nose bleed &gt;5 min duration
Macroscopic haematuria, either spontaneous or, if associated with an intervention, lasting &gt;24 h
Spontaneous rectal bleeding
Gingival bleeding &gt;5 min
Bleeding leading to hospitalisation or requiring surgical treatment
Bleeding leading to a transfusion of &lt;2 units of whole blood or red cells
Any other bleeding event considered clinically relevant by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Analysis</measure>
    <time_frame>18 months + 30 days follow up</time_frame>
    <description>Patients with LFT (liver function tests) increases of possible clinical significance during treatment. Increases of possible clinical significance were defined as: ≥3 x ULN (AST, ALT), ≥2 x ULN (AP), and ≥2 mg/dL (total bilirubin). Only patients with a baseline value which was not of possible clinical significance (or without any baseline value) could have a PCSA (Possible clinically significant abnormality).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Definite Acute Coronary Syndrome (ACS)</measure>
    <time_frame>day of first study drug intake until last day of study drug intake; from the day after last intake of study drug until trial termination</time_frame>
    <description>All suspected ACS occurring during the trial were to be recorded on the CRF and were to be centrally adjudicated by an independent ACS/AC in a treatment-blinded manner.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2867</enrollment>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin (INR of 2.0-3.0)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Dabigatran 150 mg BID (twice daily)</description>
    <arm_group_label>Dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin dosed individually to maintain INR 2.0-3.0</description>
    <arm_group_label>Warfarin (INR of 2.0-3.0)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Inclusion_Criteria

          -  Acute symptomatic deep vein thrombosis (DVT)

          -  Pulmonary embolism (PE) 3-12 months prior to screening, which has been documented by
             objective testing

        Exclusion criteria:

        Exclusion_Criteria

          -  Symptomatic DVT or PE at screening Interruption of anticoagulant therapy for 2 or more
             weeks during the 3-12 months of treatment for the prior VTE.

          -  Patients who in the investigators judgement are perceived as having an excessive risk
             of bleeding Elevated Aspartate aminotransferase (AST) or Alanine tranminase (ALT) &gt; 2x
             ULN

          -  Severe renal impairment (estimated creatinine clearance &lt;= 30 ml/min)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.47.01035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roxbury Crossing</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Adrogué</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bahía Blanca</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.54012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.61002 Princess Alexandra Hospital</name>
      <address>
        <city>Wooloongabba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.61004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.61003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.61006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.61005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.55010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brasília</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.55007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Campinas - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.55014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.55017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Juvene - Paraná -</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.55012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>pTO aLEGRE</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.55016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rio de Janeiro - RJ</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.55018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>São Bernardo do Campo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.55005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>São José do Rio Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35910 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Johns</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.02017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.86011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hranice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liberec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Novy Jicin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ostrava-Vitkovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tabor</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Usti nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.45008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.45009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Holbæk</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolding</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.45007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København S</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.45006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35805 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3301B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3301C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3301D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3301E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3301F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3301H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3301I Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Etienne Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3303B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Etienne Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Etienne Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3303D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Etienne Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.49017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.49018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Püttlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.30006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.30007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.30009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.36006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.36007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.36012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.36011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.36010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mysore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>new Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.97202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.97207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.97211 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.97203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.97205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.97206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.97208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.97210 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.97204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.97201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vittorio Veneto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.52036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.52039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Culiacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.52030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara, Jal.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.52027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.52034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Luis Potosí</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.31007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.31010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.31014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.31009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.64004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.64003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grafton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.64002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Otahuhu</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.64001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takapuna Auckland 9</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.47004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.47003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rud</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.47005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.48005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.48007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.48006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almada</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Covilhã</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.35105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pskov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.42104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.27007</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Randburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roodepoort</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.34012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Badalona (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.34007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cartagena. Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cuenca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.46006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.46007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.46008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.90003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.90004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.90005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.90002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.90007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.90006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Headington, Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.44011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.47.44012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2006</study_first_submitted>
  <study_first_submitted_qc>May 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2006</study_first_posted>
  <results_first_submitted>August 10, 2011</results_first_submitted>
  <results_first_submitted_qc>August 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2011</results_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran</title>
          <description>150 mg twice daily, total daily dose 300 mg</description>
        </group>
        <group group_id="P2">
          <title>Warfarin</title>
          <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1430">2866 were randomized. A total of ten did not receive treatment resulting in 2856 starting study.</participants>
                <participants group_id="P2" count="1426">2866 were randomized. A total of ten did not receive treatment resulting in 2856 starting study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1154"/>
                <participants group_id="P2" count="1145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="276"/>
                <participants group_id="P2" count="281"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason (not specified)</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The FAS consisted of all randomised patients who were documented to have taken at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran</title>
          <description>150 mg twice daily, total daily dose 300 mg</description>
        </group>
        <group group_id="B2">
          <title>Warfarin</title>
          <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1430"/>
            <count group_id="B2" value="1426"/>
            <count group_id="B3" value="2856"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.38" spread="14.99"/>
                    <measurement group_id="B2" value="53.90" spread="15.34"/>
                    <measurement group_id="B3" value="54.64" spread="15.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=18 to &lt;40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40 to &lt;50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                    <measurement group_id="B2" value="291"/>
                    <measurement group_id="B3" value="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50 to &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="459"/>
                    <measurement group_id="B3" value="959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 to &lt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="303"/>
                    <measurement group_id="B2" value="288"/>
                    <measurement group_id="B3" value="591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="559"/>
                    <measurement group_id="B2" value="555"/>
                    <measurement group_id="B3" value="1114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="871"/>
                    <measurement group_id="B2" value="871"/>
                    <measurement group_id="B3" value="1742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1325"/>
                    <measurement group_id="B2" value="1317"/>
                    <measurement group_id="B3" value="2642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1288"/>
                    <measurement group_id="B2" value="1284"/>
                    <measurement group_id="B3" value="2572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <description>N = 1429, 1424, 2853</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.55" spread="9.73"/>
                    <measurement group_id="B2" value="171.95" spread="10.08"/>
                    <measurement group_id="B3" value="171.75" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>N = 1429, 1422, 2851</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.09" spread="19.26"/>
                    <measurement group_id="B2" value="85.95" spread="18.87"/>
                    <measurement group_id="B3" value="86.02" spread="19.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight category</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 50 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 50 to &lt; 100 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1120"/>
                    <measurement group_id="B2" value="1117"/>
                    <measurement group_id="B3" value="2237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 100 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>N = 1428, 1422, 2850</description>
          <units>kg/square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.15" spread="5.65"/>
                    <measurement group_id="B2" value="29.01" spread="5.75"/>
                    <measurement group_id="B3" value="29.08" spread="5.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) category</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;25 kg/square meter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="334"/>
                    <measurement group_id="B3" value="649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=25 to &lt;30 kg/square meter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="571"/>
                    <measurement group_id="B2" value="584"/>
                    <measurement group_id="B3" value="1155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30 to &lt;35 kg/square meter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="356"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 35 kg/square meter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="814"/>
                    <measurement group_id="B2" value="829"/>
                    <measurement group_id="B3" value="1643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="393"/>
                    <measurement group_id="B2" value="366"/>
                    <measurement group_id="B3" value="759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum creatinine clearance</title>
          <description>N = 1418, 1410, 2828</description>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104.2" spread="38.6"/>
                    <measurement group_id="B2" value="106.6" spread="37.9"/>
                    <measurement group_id="B3" value="105.4" spread="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum creatinine clearance category</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=0 to &lt;30 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30 to &lt;50 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50 to &lt;80 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="328"/>
                    <measurement group_id="B2" value="289"/>
                    <measurement group_id="B3" value="617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 80 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1031"/>
                    <measurement group_id="B2" value="1072"/>
                    <measurement group_id="B3" value="2103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite of Recurrent VTE or VTE Death at 36 Months</title>
        <description>Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE.</description>
        <time_frame>36 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Recurrent VTE or VTE Death at 36 Months</title>
          <description>Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with no event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1404"/>
                    <measurement group_id="O2" value="1408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Comparisons between treatment groups were performed using a Cox regression analysis with treatment and baseline stratification factor in the model.</non_inferiority_desc>
            <p_value>0.0137</p_value>
            <p_value_desc>p-value for non-inferiority. The non-inferiority margin for the hazard ratio was chosen to be 2.85.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>HR within cohort estimated by Cox regr. with treatment and baseline stratific. factor. Overall HR calc. by pooling with inverse variance weighting.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>2.64</ci_upper_limit>
            <estimate_desc>HR for time to first recurrent VTE or VTE death.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2424</p_value>
            <p_value_desc>p-value for superiority. If non-inferiority could be established for HR and for the risk difference, the upper bound of the 95% CI for the hazard ratio was then compared with 1 to evaluate the superiority claim of dabigatran over warfarin.</p_value_desc>
            <method>Regression, Cox</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composite of Recurrent VTE or VTE Death at 18 Months</title>
        <description>Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE.</description>
        <time_frame>18 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Recurrent VTE or VTE Death at 18 Months</title>
          <description>Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with no event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1408"/>
                    <measurement group_id="O2" value="1409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Comparisons between treatment groups were performed using a Cox regression analysis with treatment and baseline stratification factor in the model.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value for non-inferiority. The non-inferiority margin for the risk difference was chosen to be 2.80.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Risk difference for time to first recurrent VTE/VTE death is calculated based on weighted KM estimates across the cohorts via meta-analysis approach.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4013</p_value>
            <p_value_desc>p-value for superiority. If non-inferiority could be established for HR and for the risk difference, the upper bound of the 95% CI for the risk difference was then compared with 0 to evaluate the superiority claim of dabigatran over warfarin.</p_value_desc>
            <method>Kaplan-Meier</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Recurrent VTE or All Cause Death at 36 Months</title>
        <description>Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation.</description>
        <time_frame>36 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Recurrent VTE or All Cause Death at 36 Months</title>
          <description>Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with no event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1388"/>
                    <measurement group_id="O2" value="1390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4732</p_value>
            <method>Regression, Cox</method>
            <method_desc>Hazard ratio estimated using the Cox regression with treatment, cohort, baseline stratification factors and their interaction.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
            <estimate_desc>HR for time to first centrally adjudicated recurrent VTE or all cause death.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Recurrent VTE or All Cause Death at 18 Months</title>
        <description>Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation.</description>
        <time_frame>18 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Recurrent VTE or All Cause Death at 18 Months</title>
          <description>Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with no event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1394"/>
                    <measurement group_id="O2" value="1394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran versus Warfarin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8876</p_value>
            <method>Kaplan-Meier</method>
            <method_desc>Risk difference for the time to first centrally adjudicated recurrent VTE or all cause death at month 18.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deep Vein Thrombosis (DVT) at 36 Months</title>
        <description>Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation.</description>
        <time_frame>36 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Deep Vein Thrombosis (DVT) at 36 Months</title>
          <description>Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with no event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1413"/>
                    <measurement group_id="O2" value="1413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran versus Warfarin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4548</p_value>
            <method>Regression, Cox</method>
            <method_desc>Hazard ratio estimated using the Cox regression with treatment, cohort, baseline stratification factors and their interaction.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>2.71</ci_upper_limit>
            <estimate_desc>HR for time to first centrally adjudicated recurrent symptomatic DVT</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DVT at 18 Months</title>
        <description>Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation.</description>
        <time_frame>18 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>DVT at 18 Months</title>
          <description>Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with no event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1415"/>
                    <measurement group_id="O2" value="1414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran versus Warfarin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6563</p_value>
            <method>Kaplan-Meier</method>
            <method_desc>Risk difference for the time to first centrally adjudicated recurrent symptomatic DVT at Month 18.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptomatic Pulmonary Embolism (PE) at 36 Months</title>
        <description>Symptomatic pulmonary embolism (PE) at 36 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.</description>
        <time_frame>36 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Symptomatic Pulmonary Embolism (PE) at 36 Months</title>
          <description>Symptomatic pulmonary embolism (PE) at 36 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with no event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1420"/>
                    <measurement group_id="O2" value="1421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran versus Warfarin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1925</p_value>
            <method>Regression, Cox</method>
            <method_desc>Hazard ratio estimated using the Cox regression with treatment, cohort, baseline stratification factors and their interaction.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>5.98</ci_upper_limit>
            <estimate_desc>Hazard ratio for time to first centrally adjudicated recurrent symptomatic PE.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptomatic Pulmonary Embolism (PE) at 18 Months</title>
        <description>Symptomatic pulmonary embolism (PE) at 18 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.</description>
        <time_frame>18 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Symptomatic Pulmonary Embolism (PE) at 18 Months</title>
          <description>Symptomatic pulmonary embolism (PE) at 18 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with no event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1422"/>
                    <measurement group_id="O2" value="1421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran versus Warfarin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3723</p_value>
            <method>Kaplan-Meier</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
            <estimate_desc>Risk difference for the time to first centrally adjudicated recurrent symptomatic PE at Month 18</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deaths Related to VTE at 36 Months</title>
        <description>Deaths related to VTE (i.e. fatal PE) at 36 Months. Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.</description>
        <time_frame>36 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Deaths Related to VTE at 36 Months</title>
          <description>Deaths related to VTE (i.e. fatal PE) at 36 Months. Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with no event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1429"/>
                    <measurement group_id="O2" value="1425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran versus Warfarin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9921</p_value>
            <method>Regression, Cox</method>
            <method_desc>Hazard ratio estimated using the Cox regression with treatment, cohort, baseline stratification factors and their interaction.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>16.22</ci_upper_limit>
            <estimate_desc>Hazard ratio for time to deaths related to VTE.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deaths Related to VTE at 18 Months</title>
        <description>Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.</description>
        <time_frame>18 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Deaths Related to VTE at 18 Months</title>
          <description>Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with no event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1429"/>
                    <measurement group_id="O2" value="1425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran versus Warfarin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9204</p_value>
            <method>Kaplan-Meier</method>
            <method_desc>Risk difference for the time to deaths related to VTE at Month 18.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deaths of All Causes at 36 Months</title>
        <description>Deaths of all causes at 36 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.</description>
        <time_frame>36 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Deaths of All Causes at 36 Months</title>
          <description>Deaths of all causes at 36 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with no event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1413"/>
                    <measurement group_id="O2" value="1407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran versus Warfarin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7405</p_value>
            <method>Regression, Cox</method>
            <method_desc>Hazard ratio estimated using the Cox regression with treatment, cohort, baseline stratification factors and their interaction.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
            <estimate_desc>Hazard ratio for time to all deaths</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deaths of All Causes at 18 Months</title>
        <description>Deaths of all causes at 18 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.</description>
        <time_frame>18 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Deaths of All Causes at 18 Months</title>
          <description>Deaths of all causes at 18 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with no event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1415"/>
                    <measurement group_id="O2" value="1410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dabigatran versus Warfarin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9622</p_value>
            <method>Kaplan-Meier</method>
            <method_desc>Risk difference for the time to all deaths at Month 18.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Events</title>
        <description>MBE (major bleeding event) if it fulfilled at least one of the following criteria
Fatal bleeding
Symptomatic bleeding in a critical area or organ.
Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.
Minor bleeding event was any bleeding that did not fulfil any of the criteria for MBEs
CRBE (clinically relevant bleeding event) if it is a minor bleeding events which fulfilled at least one of the following criteria
Spontaneous skin haematoma ≥25 cm2
Spontaneous nose bleed &gt;5 min duration
Macroscopic haematuria, either spontaneous or, if associated with an intervention, lasting &gt;24 h
Spontaneous rectal bleeding
Gingival bleeding &gt;5 min
Bleeding leading to hospitalisation or requiring surgical treatment
Bleeding leading to a transfusion of &lt;2 units of whole blood or red cells
Any other bleeding event considered clinically relevant by the investigator</description>
        <time_frame>first intake of study drug until 6 days following last intake of study drug</time_frame>
        <population>FAS as treated</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Events</title>
          <description>MBE (major bleeding event) if it fulfilled at least one of the following criteria
Fatal bleeding
Symptomatic bleeding in a critical area or organ.
Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.
Minor bleeding event was any bleeding that did not fulfil any of the criteria for MBEs
CRBE (clinically relevant bleeding event) if it is a minor bleeding events which fulfilled at least one of the following criteria
Spontaneous skin haematoma ≥25 cm2
Spontaneous nose bleed &gt;5 min duration
Macroscopic haematuria, either spontaneous or, if associated with an intervention, lasting &gt;24 h
Spontaneous rectal bleeding
Gingival bleeding &gt;5 min
Bleeding leading to hospitalisation or requiring surgical treatment
Bleeding leading to a transfusion of &lt;2 units of whole blood or red cells
Any other bleeding event considered clinically relevant by the investigator</description>
          <population>FAS as treated</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>patients with MBE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>patients with MBE and /or CRBE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>patients with any bleeding event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                    <measurement group_id="O2" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio estimated using the Cox regression with treatment, cohort, baseline stratification factors (including active cancer at baseline and symptomatic PE as qualifying event) and their interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0577</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>This is the analysis of the time to the first MBE.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio estimated using the Cox regression with treatment, cohort, baseline stratification factors (including active cancer at baseline and symptomatic PE as qualifying event) and their interaction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
            <estimate_desc>This is the analysis of the time to the first occurrence of any bleeding event.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Analysis</title>
        <description>Patients with LFT (liver function tests) increases of possible clinical significance during treatment. Increases of possible clinical significance were defined as: ≥3 x ULN (AST, ALT), ≥2 x ULN (AP), and ≥2 mg/dL (total bilirubin). Only patients with a baseline value which was not of possible clinical significance (or without any baseline value) could have a PCSA (Possible clinically significant abnormality).</description>
        <time_frame>18 months + 30 days follow up</time_frame>
        <population>FAS as treated</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Analysis</title>
          <description>Patients with LFT (liver function tests) increases of possible clinical significance during treatment. Increases of possible clinical significance were defined as: ≥3 x ULN (AST, ALT), ≥2 x ULN (AP), and ≥2 mg/dL (total bilirubin). Only patients with a baseline value which was not of possible clinical significance (or without any baseline value) could have a PCSA (Possible clinically significant abnormality).</description>
          <population>FAS as treated</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1411"/>
                <count group_id="O2" value="1402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Definite Acute Coronary Syndrome (ACS)</title>
        <description>All suspected ACS occurring during the trial were to be recorded on the CRF and were to be centrally adjudicated by an independent ACS/AC in a treatment-blinded manner.</description>
        <time_frame>day of first study drug intake until last day of study drug intake; from the day after last intake of study drug until trial termination</time_frame>
        <population>FAS as treated</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>150 mg twice daily, total daily dose 300 mg</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Definite Acute Coronary Syndrome (ACS)</title>
          <description>All suspected ACS occurring during the trial were to be recorded on the CRF and were to be centrally adjudicated by an independent ACS/AC in a treatment-blinded manner.</description>
          <population>FAS as treated</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1415"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>During intake of study drug, N=1430 , N=1415</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After stopping study drug, N=1426, N=1400</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18-month treatment period</time_frame>
      <desc>30-day follow-up period subsequent to the completion of treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran</title>
          <description>150 mg twice daily, total daily dose 300 mg</description>
        </group>
        <group group_id="E2">
          <title>Warfarin</title>
          <description>Target International Normalized Ratio (INR) of 2.0 to 3.0</description>
        </group>
        <group group_id="E3">
          <title>Post Dabigatran</title>
        </group>
        <group group_id="E4">
          <title>Post Warfarin</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="224" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Anaemia megaloblastic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Vitello-intestinal duct remnant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Retinal vascular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Trichiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Faecal vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Intestinal strangulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Peritoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Diapedesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gingival abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gnathostomiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Meningococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Purulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Purulent discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental drug intake by child</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Chemical peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Drug exposure during pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Arteriogram coronary normal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Coagulation time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Periostitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Bone cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Chondrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Gastrointestinal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Metastases to bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Metastases to retroperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Morton's neuroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Omentum neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Ovarian cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Penis carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Tumour invasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Carotid artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Diabetic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Facial neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Epididymal enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Eosinophilic pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Vascular purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Colostomy closure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Femoral hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Finger amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Incisional hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Arterial insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Post thrombotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="409" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="415" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="1384"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1430"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="1426"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1395"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1384"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

